← Back to Search

Lipase Inhibitor

Xenical (Orlistat) for Heart Disease

Phase 4
Waitlist Available
Led By Jiri Frohlich, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

The purpose of this study is to determine the effect of using the weight loss medication Xenical (generic name - orlistat) on weight loss and change in heart disease risk factors in patients of the Healthy Heart Program Lipid Clinic at St. Paul's Hospital over a three month period. Xenical works by blocking the body's absorption of dietary fat in the gut, allowing it to pass through to be excreted, therefore reducing the intake of fat and calories. This is a pilot study supported by Hoffmann-La Roche Limited which produces Xenical. The aim is to investigate whether weight loss will also result in reductions in heart disease risk factors that may allow for less of a need for medications controlling lipid levels, hypertension and plasma glucose.

Eligible Conditions
  • Heart Disease
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: Xenical (Orlistat)Experimental Treatment1 Intervention
Investigating the effectiveness of Xenical on cardiovascular risk factors in the patients of St. Paul's Hospital Lipid Clinic
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Orlistat
FDA approved

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,454 Previous Clinical Trials
2,483,350 Total Patients Enrolled
Jiri Frohlich, MDPrincipal InvestigatorUniversity of British Columbia
4 Previous Clinical Trials
683 Total Patients Enrolled
~1 spots leftby Sep 2025